These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4027997)

  • 21. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.
    Kipp BR; Karnes RJ; Brankley SM; Harwood AR; Pankratz VS; Sebo TJ; Blute MM; Lieber MM; Zincke H; Halling KC
    J Urol; 2005 Feb; 173(2):401-4. PubMed ID: 15643180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin].
    Ito Y; Nishiyama H; Higashi S; Kinoshita H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2004 May; 50(5):335-8. PubMed ID: 15237488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.
    Mengual L; Marín-Aguilera M; Ribal MJ; Burset M; Villavicencio H; Oliver A; Alcaraz A
    Eur Urol; 2007 Sep; 52(3):752-9. PubMed ID: 17379395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
    Losa A; Hurle R; Lembo A
    J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
    de Boer EC; De Reijke TM; Vos PC; Kurth KH; Schamhart DH
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S109-14. PubMed ID: 11010835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
    Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
    Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [BCG infection of the glans penis after intravesical BCG therapy].
    Michelet N; Spenatto N; Viraben R; Cuny JF; Mazet J; Trechot P; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2008; 135(6-7):479-83. PubMed ID: 18598797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stromal invasion of the prostate following a complete response to bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the ureter and the bladder.
    Hara I; Yao A; Muramaki M; Hikosaka S; Yamada Y; Kawabata G; Kamidono S
    Int J Urol; 2004 Apr; 11(4):250-2. PubMed ID: 15028107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Carcinoma in situ of the bladder involving the prostate with an unusual invasive pattern following BCG therapy: a case report].
    Iba A; Kohjimoto Y; Inagaki T; Suzuki A; Fujii R; Senzaki H; Uekado Y; Shinka T
    Hinyokika Kiyo; 2005 Oct; 51(10):681-4. PubMed ID: 16285623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors.
    Pages F; Flam TA; Vieillefond A; Molinie V; Abeille X; Lazar V; Bressac-de Paillerets B; Mosseri V; Zerbib M; Fridman WH; Debré B; Thiounn N
    J Urol; 1998 Mar; 159(3):1079-84. PubMed ID: 9474235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.